Showing results (51-60 of 320) with videos related to
Sort By:
Pageof 32
Biochemical Pharmacology|March 13, 2012
Structure-dependent activation of NR4A2 (Nurr1) by 1,1-bis(3'-indolyl)-1-(aromatic)methane analogs in pancreatic cancer cellsXi Li, Syng-Ook Lee, Stephen SafeCancer Research|November 20, 2016
PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1Alexandra Lacey, Aline Rodrigues-Hoffman, Stephen SafeMolecular Carcinogenesis|June 30, 2004
Estrogen-dependent regulation of ornithine decarboxylase in breast cancer cells through activation of nongenomic cAMP-dependent pathwaysChunhua Qin, Ismael Samudio, Sharon Ngwenya, et al.Neuroscience Letters|September 19, 2015
A novel synthetic activator of Nurr1 induces dopaminergic gene expression and protects against 6-hydroxydopamine neurotoxicity in vitroSean L Hammond, Stephen Safe, Ronald B TjalkensJournal of Rnai and Gene Silencing : an International Journal of RNA and Gene Targeting Research|September 23, 2009
RNAi and cancer: Implications and applicationsMaen Abdelrahim, Stephen Safe, Cheryl Baker, et al.Molecular Cancer Research : MCR|April 22, 2010
Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cellsGayathri Chadalapaka, Indira Jutooru, Robert Burghardt, et al.Journal of Molecular Endocrinology|October 28, 2008
Role of SP transcription factors in hormone-dependent modulation of genes in MCF-7 breast cancer cells: microarray and RNA interference studiesFei Wu, Ivan Ivanov, Rui Xu, et al.Toxicology and Applied Pharmacology|July 30, 2017
Inactivation of the orphan nuclear receptor NR4A1 contributes to apoptosis induction by fangchinoline in pancreatic cancer cellsHyo-Seon Lee, Stephen Safe, Syng-Ook LeeMolecular Cancer Research : MCR|August 30, 2019
Inhibition of NR4A1 Promotes ROS Accumulation and IL24-Dependent Growth Arrest in RhabdomyosarcomaErik Hedrick, Kumaravel Mohankumar, Alexandra Lacey, et al.The Journal of Pharmacology and Experimental Therapeutics|August 11, 2012
Aryl hydrocarbon receptor (AHR)-active pharmaceuticals are selective AHR modulators in MDA-MB-468 and BT474 breast cancer cellsUn-Ho Jin, Syng-ook Lee, Stephen SafePageof 32